Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

1.400 +0.180 (+14.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
A Look Into Healthcare Sector Value Stocks ↗
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Aytu BioPharma (NASDAQ:AYTU) stock increased by 19.36% to $6.41 during Tuesday's pre-market session. The market value of their outstanding shares is at $161.3... 
Via Benzinga
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Bionano Genomics (NASDAQ:BNGO) st... 
Via Benzinga
News headline image
Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions ↗
Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021 ↗
Upgrades Compass Point upgraded the previous rating for Newtek Business Services Corp (NASDAQ:NEWT) from Neutral to Buy. For the fourth quarter, Newtek Business Services... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.